TEVA Teva Pharmaceutical Industries Ltd - 8-K

Item 5.07

Submission of Matters to a Vote of Security Holders.

Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) held its Annual Meeting on May 28, 2026 (the “Annual Meeting”). The following is a summary of the matters voted on at the meeting.

(1) The shareholders elected to appoint the following person to the Board, to serve until Teva’s 2029 annual meeting of shareholders, as follows:

For

Against

Abstain

Broker

non-votes

Dr. Sol J. Barer

627,816,662

245,921,571

530,682

50,661,570

(2) The shareholders approved, on a non-binding advisory basis, the compensation for Teva’s named executive officers listed in the proxy statement for the Annual Meeting, as follows:

For

Against

Abstain

Broker non-votes

795,976,042

77,082,847

1,170,026

50,661,570

(3) The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2027 annual meeting of shareholders, as follows:

For

Against

Abstain

Broker non-votes

880,542,242

36,085,507

525,382

0